Evidence map›Paper›PMID 37280036›Full record

ArticleBMJ open2023

Efficacy of alcohol reduction interventions among people with HIV as evaluated by self-report and a phosphatidylethanol (PEth) outcome: protocol for a systematic review and individual participant data meta-analysis.

Jeremy C Kane, Isabel Allen, Robin Fatch, Aaron Scheffler, Nneka Emenyonu, Sarah B Puryear, Priya Chirayil, Kaku So-Armah, Christopher W Kahler, Jessica F Magidson and 15 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 16 institutions in 4 countries.

Jeremy C KaneEpidemiology, Columbia University Mailman School of Public Health, New York, New York, USA jk4397@cumc.columbia.edu.ORCID 0000-0002-6598-3840
Isabel AllenEpidemiology & Biostatistics, University of California, San Francisco, California, USA.ORCID 0000-0001-9029-9744
Robin FatchMedicine, University of California, San Francisco, California, USA.
Aaron SchefflerEpidemiology & Biostatistics, University of California, San Francisco, California, USA.
Nneka EmenyonuMedicine, University of California, San Francisco, California, USA.
Sarah B PuryearMedicine, University of California, San Francisco, California, USA.
Priya ChirayilEpidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.
Kaku So-ArmahSchool of Medicine, Boston University, Boston, Massachusetts, USA.
Christopher W KahlerCenter for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island, USA.ORCID 0000-0002-6248-4149
Jessica F MagidsonPsychology, University of Maryland, College Park, Maryland, USA.
Amy A ConroyMedicine, University of California, San Francisco, California, USA.
E Jennifer EdelmanYale School of Medicine, New Haven, Connecticut, USA.
Sarah Woolf-KingPsychology, Syracuse University, Syracuse, New York, USA.
Charles ParryMental Health, Alcohol, Substance Use & Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.
Susan M KieneEpidemiology and Biostatistics, San Diego State University College of Health and Human Services School of Public Health, San Diego, California, USA.
Gabriel ChamieMedicine, University of California, San Francisco, California, USA.
Julian AdongMakerere University School of Public Health, Kampala, Uganda.
Vivian F GoDepartment of Health Behavior, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Robert L CookEpidemiology, University of Florida, Gainesville, Florida, USA.
Winnie MuyindikeMbarara National Referral Hospital, Mbarara, Uganda.
Neo MorojeleUniversity of Johannesburg, Auckland Park, South Africa.
Elena BlokhinaGlobal Health Institute, St. Petersburg, Russian Federation.
Evgeny KrupitskyV.M. Bekhterev National Medical Research Center for Psychiatry and Neuroology, St. Petersburg, Russian Federation.
David A FiellinYale School of Medicine, New Haven, Connecticut, USA.
Judith A HahnEpidemiology & Biostatistics, University of California, San Francisco, California, USA.ORCID 0000-0002-2697-8264
University of California, San Francisco · USYale University · USBoston University · USBrown University · USColumbia University · USColumbia University Irving Medical Center · USMakerere University · UGMbarara National Referral Hospital · UGSan Diego State University · USSouth African Medical Research Council · ZASt.Petersburg V.M.Bekhterev Psychoneurological Research Institute · RUSyracuse University · USUniversity of Florida · USUniversity of Johannesburg · ZAUniversity of Maryland, College Park · USUniversity of North Carolina at Chapel Hill · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
Training in Research Program on Alcohol Use by Persons with our at Risk for HIVK24AA022586 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2013 to 2023
$1.8M
Biomarkers for Alcohol/HIV Research (BAHR) StudyR01AA029962 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2022 to 2024
$1.8M
Improving measurement of alcohol consumption among HIV-affected youth in sub-Saharan Africa: evaluation and implementation of biomarkersK01AA026523 · NIAAA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KANE, JEREMY CALVIN · 2020 to 2024
$881k
Understanding alcohol misuse and its impact on viral suppression in youth living with HIV in East AfricaK23AA029045 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PURYEAR, SARAH BROWN · 2020 to 2023
$807k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K01 AA026523NIAAA NIH HHS K23 AA029045NIAAA NIH HHS K24 AA022586NIAAA NIH HHS R01 AA029962NIMH NIH HHS P30 MH062246NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

introductionUnhealthy alcohol use is associated with a range of adverse outcomes among people with HIV (PWH). Testing the efficacy and promoting the availability of effective interventions to address unhealthy alcohol use among PWH is thus a priority. Alcohol use outcomes in intervention studies are often measured by self-report alone, which can lead to spurious results due to information biases (eg, social desirability). Measuring alcohol outcomes objectively through biomarkers, such as phosphatidylethanol (PEth), in addition to self-report has potential to improve the validity of intervention studies. This protocol outlines the methods for a systematic review and individual participant data meta-analysis that will estimate the efficacy of interventions to reduce alcohol use as measured by a combined categorical self-report/PEth variable among PWH and compare these estimates to those generated when alcohol is measured by self-report or PEth alone. METHODS AND ANALYSIS: We will include randomised controlled trials that: (A) tested an alcohol intervention (behavioural and/or pharmacological), (B) enrolled participants 15 years or older with HIV; (C) included both PEth and self-report measurements, (D) completed data collection by 31 August 2023. We will contact principal investigators of eligible studies to inquire about their willingness to contribute data. The primary outcome variable will be a combined self-report/PEth alcohol categorical variable. Secondary outcomes will include PEth alone, self-report alone and HIV viral suppression. We will use a two-step meta-analysis and random effects modelling to estimate pooled treatment effects; I ETHICS AND DISSEMINATION: The study will be conducted with deidentified data from completed randomised controlled trials and will be considered exempt from additional ethical approval. Results will be disseminated through peer-reviewed publications and international scientific meetings. PROSPERO REGISTRATION NUMBER: CRD42022373640.

Indexed as

Alcohol DrinkingHIV InfectionsEthanolGlycerophospholipidsHumansMeta-Analysis as TopicSelf ReportSystematic Reviews as TopicEthanolGlycerophospholipidsphosphatidylethanolclinical trialsHIV & AIDSsubstance misuse

Identifiers

PMID37280036
PMCPMC10254608
OpenAlexW4379600130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.